PT867192E - Preparado combinado para utilizacao na demencia, contendo pelo menos um composto que apresenta um efeito de inibicao da esterase da acetilcolina ou um efeito muscarinico e um composto que eleva o nivel endogeno extracelular da adenosina - Google Patents

Preparado combinado para utilizacao na demencia, contendo pelo menos um composto que apresenta um efeito de inibicao da esterase da acetilcolina ou um efeito muscarinico e um composto que eleva o nivel endogeno extracelular da adenosina

Info

Publication number
PT867192E
PT867192E PT98102620T PT98102620T PT867192E PT 867192 E PT867192 E PT 867192E PT 98102620 T PT98102620 T PT 98102620T PT 98102620 T PT98102620 T PT 98102620T PT 867192 E PT867192 E PT 867192E
Authority
PT
Portugal
Prior art keywords
acetylcoline
endogene
adenosin
esterase
dementia
Prior art date
Application number
PT98102620T
Other languages
English (en)
Inventor
Schubert Hans-Peter
Nimmesgern Hildegard
Rudolphi Karl
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PT867192E publication Critical patent/PT867192E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PT98102620T 1997-02-26 1998-02-16 Preparado combinado para utilizacao na demencia, contendo pelo menos um composto que apresenta um efeito de inibicao da esterase da acetilcolina ou um efeito muscarinico e um composto que eleva o nivel endogeno extracelular da adenosina PT867192E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19707655A DE19707655A1 (de) 1997-02-26 1997-02-26 Kombinationspräparat zur Anwendung bei Demenz

Publications (1)

Publication Number Publication Date
PT867192E true PT867192E (pt) 2005-08-31

Family

ID=7821517

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98102620T PT867192E (pt) 1997-02-26 1998-02-16 Preparado combinado para utilizacao na demencia, contendo pelo menos um composto que apresenta um efeito de inibicao da esterase da acetilcolina ou um efeito muscarinico e um composto que eleva o nivel endogeno extracelular da adenosina

Country Status (30)

Country Link
US (1) US6037347A (pt)
EP (1) EP0867192B1 (pt)
JP (1) JP4374440B2 (pt)
KR (1) KR100517186B1 (pt)
CN (1) CN100363005C (pt)
AR (1) AR011860A1 (pt)
AT (1) ATE295738T1 (pt)
AU (1) AU749278C (pt)
BR (1) BR9800766A (pt)
CA (1) CA2230350C (pt)
CZ (1) CZ298367B6 (pt)
DE (2) DE19707655A1 (pt)
DK (1) DK0867192T3 (pt)
EE (1) EE03387B1 (pt)
ES (1) ES2242243T3 (pt)
HR (1) HRP980097B1 (pt)
HU (1) HUP9800396A3 (pt)
ID (1) ID19941A (pt)
IL (1) IL123453A (pt)
MY (1) MY120530A (pt)
NO (1) NO327200B1 (pt)
NZ (1) NZ329839A (pt)
PL (1) PL191576B1 (pt)
PT (1) PT867192E (pt)
RU (1) RU2194508C2 (pt)
SI (1) SI0867192T1 (pt)
SK (1) SK284925B6 (pt)
TR (1) TR199800302A2 (pt)
TW (1) TW590772B (pt)
ZA (1) ZA981561B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914251A (pt) * 1998-10-01 2001-06-19 Novartis Ag Formulações orais de liberação sustentada
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
AU2003270446A1 (en) * 2002-09-25 2004-04-19 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
AU2005320547B2 (en) 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
AU2006241771B2 (en) * 2005-04-28 2010-09-09 Eisai R & D Management Co., Ltd. Composition containing anti-dementia drug
EP3347011A4 (en) 2015-09-11 2019-06-19 Chase Pharmaceuticals Corporation MUSCARIN COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGEN DISORDERS OF THE CENTRAL NERVOUS SYSTEM
RU2616247C1 (ru) * 2016-03-28 2017-04-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинский государственный университет имени Коста Левановича Хетагурова" (СОГУ) Твердая лекарственная форма, обладающая холинопозитивным действием, на основе 9-бутиламино-3,3-диметил-1,2,4-тригидроакридина

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737433A (en) * 1964-09-05 1973-06-05 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines
US3621096A (en) * 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
DE2330742C2 (de) * 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
JPH062675B2 (ja) * 1985-04-05 1994-01-12 ヘキストジヤパン株式会社 記憶障害治療剤
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
IL81610A (en) * 1986-02-27 1990-12-23 Roussel Uclaf Derivatives of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime,their preparation and pharmaceutical compositions containing them
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
IL87861A0 (en) * 1987-10-05 1989-03-31 Pfizer 4-aminopyridine derivatives
WO1989002739A1 (en) * 1987-10-05 1989-04-06 Pfizer Inc. 4-aminopyridine derivatives
DE3817955A1 (de) * 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
EP0491792A4 (en) * 1989-09-15 1992-12-02 Gensia Pharmaceuticals, Inc. Methods of treating neurodegenerative conditions
DE4236331A1 (de) * 1992-10-28 1994-05-05 Boehringer Ingelheim Kg Synergistische Kombination
US5783584A (en) * 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment

Also Published As

Publication number Publication date
CA2230350A1 (en) 1998-08-26
RU2194508C2 (ru) 2002-12-20
HU9800396D0 (en) 1998-04-28
CN100363005C (zh) 2008-01-23
SI0867192T1 (en) 2005-10-31
JP4374440B2 (ja) 2009-12-02
KR100517186B1 (ko) 2005-12-05
PL325074A1 (en) 1998-08-31
TR199800302A3 (tr) 1998-09-21
BR9800766A (pt) 1999-12-07
DK0867192T3 (da) 2005-09-05
IL123453A (en) 2004-06-20
ID19941A (id) 1998-08-27
HUP9800396A1 (hu) 1999-07-28
HUP9800396A3 (en) 2001-05-28
US6037347A (en) 2000-03-14
DE19707655A1 (de) 1998-08-27
AU749278C (en) 2003-07-31
MY120530A (en) 2005-11-30
KR19980071717A (ko) 1998-10-26
HRP980097A2 (en) 1998-12-31
DE59812801D1 (de) 2005-06-23
CN1192904A (zh) 1998-09-16
AU5627398A (en) 1998-09-03
EE03387B1 (et) 2001-04-16
AR011860A1 (es) 2000-09-13
NO980786L (no) 1998-08-27
EP0867192A3 (de) 2000-12-06
ZA981561B (en) 1998-08-26
SK284925B6 (sk) 2006-02-02
JPH10236979A (ja) 1998-09-08
ATE295738T1 (de) 2005-06-15
EP0867192B1 (de) 2005-05-18
NZ329839A (en) 2000-05-26
CZ54098A3 (cs) 1998-09-16
TR199800302A2 (xx) 1998-09-21
CZ298367B6 (cs) 2007-09-12
SK24098A3 (en) 1998-09-09
HRP980097B1 (en) 2006-09-30
ES2242243T3 (es) 2005-11-01
NO327200B1 (no) 2009-05-11
EE9800075A (et) 1998-10-15
EP0867192A2 (de) 1998-09-30
AU749278B2 (en) 2002-06-20
TW590772B (en) 2004-06-11
IL123453A0 (en) 1998-09-24
PL191576B1 (pl) 2006-06-30
MX9801515A (es) 1998-08-30
NO980786D0 (no) 1998-02-25
CA2230350C (en) 2007-07-24

Similar Documents

Publication Publication Date Title
MX9205432A (es) Compuestos inhibidores de la biosintesis de leucotrienos y composicion farmaceutica que los contiene.
MX9203373A (es) 3-amino-1-hidroxi-propan-1,1-difosfonato disodico y composiciones farmaceuticas que lo contienen.
ES2016585B3 (es) Polibutilaminas y poliisobutilaminas, procedimiento para su preparacion y composiciones combustibles y lubricantes que contienen estas sustancias.
NO852887L (no) Modifiserte succinimider, fremgangsmaate for deres fremstilling samt smoereolje- og drivstoffblandinger som inneholder disse.
BR9814714B1 (pt) processo para o controle de que o grupo de cigarros esteja com a quantidade completa e do enchimento dos cigarros.
NO944512L (no) Fremgangsmåte for behandling av oljebrönn
PT846110E (pt) Sulfonamidas contendo thf que sao inibidores de apartil-protease
NO952651D0 (no) Absorberende gjenstand av bleie-eller innleggstypen samt innlegg dertil
FI973475A (fi) Koostumus ja sitä sisältävä tuote
DE69625769D1 (de) Verteiler zur unabhängigen Ein- und/oder Abführung von Fluiden
BR9406348A (pt) Composiçao e processo para detetar um ligante e a presença ou quantidade do mesmo
PT867192E (pt) Preparado combinado para utilizacao na demencia, contendo pelo menos um composto que apresenta um efeito de inibicao da esterase da acetilcolina ou um efeito muscarinico e um composto que eleva o nivel endogeno extracelular da adenosina
NO954246D0 (no) Måler for fluidumsammensetning
BR9201087A (pt) Composicao gelificavel aquosa e processo para reducao da permeabilidade de um reservatorio de petroleo
NO955297L (no) Kupong for spill
MX9202763A (es) Nuevos derivados de 2-(1-piperazinil)-4-fenil-cicloalcanopiridina y composicion farmaceutica que los contiene.
MX9202095A (es) Nuevos 1- amino naftalenos substituidos y composicion de aceite lubricante que los contiene.
FI943391A0 (fi) Paperin päällystekoostumus
PT865236E (pt) Substrato de la mineral para plantas.
DE69415416D1 (de) Ölzusammensetzung zur Metallbearbeitung
MX9202656A (es) Compuestos de tiadiazabiciclooctano o tiadiazabicicloocteno, procedimiento para su obtencion y composicion herbicida que los contiene.
DE69400410D1 (de) 2-(Benzotriazol-2-yl)-4-alkyl-6-(2-hydroxy-3-benzoyl-benzyl)-phenole und stabilisierte Zusammensetzungen
NO901491D0 (no) Overflateaktive midler, samt deres anvendelse ved oljeutvinning.
NO901490D0 (no) Overflateaktive midler, samt deres anvendelse ved oljeutvinning.
FI2738U1 (fi) Levitin polttoainepatruunaa varten ja polttoainepatruuna